Guotai CSI Medical Service ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

CSO 实际控制 persons under investigation for disclosure violations related to shareholding changes

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Reduces Holdings in Kangbok Chemical's H Shares

BlackRock Increases Holding in Wuxi Biologics H Shares

Goldman Sachs Downgrades Taige Pharma's Profit Forecast and Target Price

HSBC Upgrades Wuxi Biologics Rating and Target Price

Three Shareholders of Kanglong Chemical Plan to Reduce 1.57% Equity

China Construction Bank Reiterates Buy Rating on Hangzhou Therasky Medical Consulting's H Shares

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

Senate Minority Leader Chuck Schumer criticized Donald Trump's recent trip to China, labeling it a 'photo op' that failed to address key issues such as fentanyl, Taiwan, U.S. manufacturing, and AI. Schumer stated that Trump returned with 'nothing to show for it' and highlighted concerns over the lack of action on fentanyl flow, protections for U.S. manufacturers, and doubts regarding U.S. commitment to Taiwan.

benzinga_article

NVIDIA

Alibaba

BABA-W

TENCENT

Tencent

NVIDIA Corporation

BABA-WR

Alibaba HK SDR 5to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Chuck Schumer Slams Trump China Trip As 'Photo Op' With Xi Jinping, Says Visit Delivers 'Nothing' On Fentanyl, Taiwan And AI

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

512170

159898

159873

159137

159828

159883

36Kr learned that CITIC Securities pointed out that the turning point for the medical device sector is approaching, and there are opportunities for performance valuation recovery for individual stocks in 2026. Focus on companies that are expected to accelerate growth in 2026 compared to 2025, which may achieve a double boost in performance valuation in the future. In 2026, the A-share medical device sector is recommended to focus on investment opportunities related to performance recovery and overseas expansion, while in the Hong Kong stock market, attention should be paid to the sector effects brought by the listing of several quality medical device companies, as well as the gradual profit release and undervalued layout opportunities of several leading companies in the medical device subsector

36Kr

Hwabao WP CSI Medical Service ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Tianhong CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

CITIC Construction Investment: The turning point for the medical device sector is approaching

510660

512010

The National Medical Products Administration released 26 industry standards for medical devices, attracting attention to medical innovation ETFs. The constituents of the CSI Medicine and Medical Device Innovation Index showed mixed performance, with the latest quote for the medical innovation ETF at 0.36 yuan and an average daily trading volume of 51.0169 million yuan. The National Medical Products Administration approved the registration of BrainCo's brain-computer interface products, marking the entry of the world's first invasive brain-computer interface medical device into clinical application. Kaiyuan Securities pointed out that the brain-computer interface industry will accelerate its development, and related companies are expected to speed up the clinical trial process

腾讯新闻 - 财经

iShares US Pharma

SPDR Pharmac

First Trust NYSE Arca Biotech Index Fd

Ping An CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

SPDR S&P Biotech

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

E Fund CSI 300 Health Care ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

GF Fund CSI Medical Service ETF

Invesco Pharmaceuticals ETF

Penghua CSI Health Care Index Fund(LOF)-A

Guotai SSE STAR Brand Name Drug ETF

GF CSI All Share Health Care ETF

VanEck Pharmaceutical ETF

China Merchants CSI Biotechnology Theme ETF

The Drug Administration announced 26 industry standards for medical devices, and medical innovation ETFs are receiving significant attention

中证医疗

159847

National Committee member Ding Lieming proposed the establishment of a long-term special fund for pharmaceutical innovation to promote the development of China's innovative drug industry. He emphasized that building a comprehensive capital support system is key, including expanding industrial investment funds and facilitating channels for listings and mergers and acquisitions. Ding Lieming pointed out that although China's innovative drug market is gradually gaining international recognition, a stable policy environment and a healthy capital ecosystem are still needed to support long-term research and development

E Fund CSI Medical Service ETF

National Committee Member Ding Lieming: Proposes that the government guide funds and state-owned capital to establish a long-term special fund for pharmaceutical innovation

Guotai CSI Medical Service ETF(159828.SZ)